Trial reportNeurology2013
CNS vasculitis in a patient with MS on daclizumab monotherapy.
Trial report in Neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Complete remission of intracranial lymphocytic vasculitis following resection: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Natural killer cells in the central nervous system.Cell communication and signaling : CCS · 2023Review
- What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us?Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2.International journal of physiology, pathophysiology and pharmacology · 2019Review
- GFAPα IgG-associated encephalitis upon daclizumab treatment of MS.Neurology(R) neuroimmunology & neuroinflammation · 2018Article
- The effects of interleukin-2 on immune response regulation.Mathematical medicine and biology : a journal of the IMA · 2018Article
- Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis.Therapeutic advances in neurological disorders · 2017Review
- Daclizumab.Hospital pharmacy · 2016Article
- Spotlight on daclizumab: its potential in the treatment of multiple sclerosis.Degenerative neurological and neuromuscular disease · 2016Review
- Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.Clinical and experimental immunology · 2014Review
- How implementation of systems biology into clinical trials accelerates understanding of diseases.Frontiers in neurology · 2014Review
- Review
- Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis.Drug design, development and therapy · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo report the development of CNS vasculitis in a patient with multiple sclerosis (MS) treated with daclizumab.
methodsThis report includes clinical, MRI, immunologic, and pathology data and CSF analysis.
resultsAfter completing a phase II daclizumab monotherapy study with an optimal response as evidenced by significant decrease in MRI disease activity and stable clinical examinations, the patient elected to continue daclizumab therapy outside of NIH study. Daclizumab was discontinued after 21 doses due to the onset of new clinical symptoms and evidence of a vascular pattern of contrast enhancement on brain and spine MRI. Because of continued clinical deterioration, stereotactic brain biopsy was performed, showing small-vessel CNS vasculitis. Treatment was initiated with IV methylprednisolone followed by a regimen of cyclophosphamide. Immunologic studies suggest that unexpected lack of expansion of CD56(bright) NK cells and predictable decline in FoxP3+ T-regs combined with a transient interruption in daclizumab dosing may have contributed to this serious side effect.
conclusionsOnly safety data from larger phase III studies and potentially postmarketing experience will define the exact risk of daclizumab-induced immunopathologies. Nevertheless, our case provides plausible hypothesis and potential biomarker that may be used to screen susceptible patients and implement preventive safety measures during potentially vulnerable periods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.